The Humanized Mouse and Rat Model Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Type (Humanized Mouse Model, CD34 Humanized Mouse Models, PBMC Humanized Mouse Models, BLT Humanized Mouse Models, Humanized Rat Model), By Application (Oncology, Immunology and Infectious Diseases, Neuroscience, Toxicology, Hematopoiesis, Others), By End-User (Pharmaceutical & Biotechnology Companies, CROs and CDMOs, Research Institutes, Others).
Humanized mouse and rat models play a pivotal role in translational research, offering valuable tools for studying human diseases, immune responses, and therapeutic interventions in vivo. In 2025, advancements in genome editing technologies, such as CRISPR-Cas9, enable precise modification of the murine and rat genomes to incorporate human genes, immune cells, or tissues, thereby creating more faithful representations of human physiology and pathology. These humanized models serve as invaluable preclinical platforms for investigating cancer immunotherapy, infectious diseases, autoimmune disorders, and regenerative medicine approaches. Furthermore, refinements in humanization protocols and immune system reconstitution techniques enhance the fidelity and reproducibility of humanized mouse and rat models, facilitating more accurate predictions of drug efficacy and toxicity. As the demand for predictive preclinical models intensifies in drug development and personalized medicine, humanized rodent models continue to play a crucial role in accelerating translational research and bridging the gap between bench and bedside.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAragen Life Sciences Pvt. Ltd, Biocytogen Inc, Champions Oncology Inc, Charles River Laboratories International Inc, Crown Bioscience Inc, Cyagen Biosciences Inc, GemPharmatech Co. Ltd, genOway S.A., Harbour Antibodies BV, Hera BioLabs Inc, Ingenious Targeting Laboratory Inc, Inotiv Inc, Oncodesign SA, Ozgene Pty Ltd, Pharmatest Services Ltd, Taconic Biosciences Inc, The Jackson Laboratory, TRANS GENIC Inc, TransCure bioServices SAS, Vitalstar Biotechnology Co. Ltd, and Others.
A prominent trend in the humanized mouse and rat model market is the increasing demand for precision medicine research. As personalized medicine gains prominence in healthcare, there is a growing need for animal models that accurately mimic human physiology and disease states. Humanized mouse and rat models, which are engineered to incorporate human cells, tissues, or immune systems, offer valuable tools for studying human-specific diseases, testing novel therapeutics, and predicting patient responses to treatments. With the rising focus on tailoring medical interventions to individual patient characteristics, the demand for humanized animal models is expected to increase, driving market growth and innovation in precision medicine research.
A primary driver fueling the growth of the humanized mouse and rat model market is the advancements in genetic engineering technologies. Recent breakthroughs in genome editing tools, such as CRISPR-Cas9, have revolutionized the field of transgenic animal modeling, enabling precise and efficient manipulation of the genome to create humanized animal models with enhanced physiological relevance. Researchers can introduce human genes, knock out or replace endogenous genes, and manipulate immune cell populations to generate humanized models that accurately recapitulate human diseases and immune responses. These technological advancements have expanded the capabilities and utility of humanized animal models, driving their adoption in biomedical research and drug discovery efforts.
An enticing opportunity within the humanized mouse and rat model market lies in the expansion into immuno-oncology and cancer immunotherapy research. Humanized animal models with functional human immune systems provide valuable platforms for studying tumor-immune interactions, tumor microenvironment dynamics, and immune checkpoint pathways in vivo. These models can be used to evaluate the efficacy and safety of immunotherapies, such as checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, in preclinical settings. By leveraging humanized animal models in immuno-oncology research, researchers can gain insights into the mechanisms of tumor immune evasion, identify predictive biomarkers of treatment response, and accelerate the development of novel cancer immunotherapies. Investing in humanized animal models for immuno-oncology applications presents opportunities for market differentiation and collaboration between academic institutions, pharmaceutical companies, and biotechnology firms to advance cancer immunotherapy research and improve patient outcomes in oncology.
The CD34 humanized mouse models have emerged as the fastest-growing segment in the Humanized Mouse and Rat Model Market. These models are characterized by the engraftment of human hematopoietic stem cells (HSCs) expressing the CD34 antigen into immunodeficient mice, leading to the reconstitution of a functional human immune system. The growth of CD34 humanized mouse models can be attributed to several factors. Firstly, there is a growing demand for preclinical models that closely mimic human physiology to facilitate the development of targeted therapies, especially in the field of oncology, immunology, and infectious diseases. CD34 humanized mouse models offer a valuable platform for studying human-specific immune responses, tumor biology, and infectious disease pathogenesis, thereby accelerating drug discovery and development efforts. Additionally, advancements in genetic engineering technologies have enabled the development of improved CD34 humanized mouse models with enhanced immune reconstitution and physiological relevance. Moreover, pharmaceutical and biotechnology companies, as well as research institutes, are increasingly recognizing the utility of CD34 humanized mouse models in their drug development pipelines, driving their adoption across the industry. Overall, the CD34 humanized mouse models represent a valuable tool for translational research and drug development, thereby fueling their rapid growth in the Humanized Mouse and Rat Model Market.
Humanized Mouse and Rat Model Market Share Analysis: Oncology Application is poised to register the fastest growth rate (CAGR) over the forecast period from 2025 to 2034.
In the Humanized Mouse and Rat Model Market, the oncology application segment is expected to lead in growth through 2034, driven by the critical role these models play in cancer research, drug development, and immunotherapy testing. Humanized rodents, which are genetically engineered to carry functional human genes, tissues, or immune systems, allow for highly predictive studies of tumor biology, drug response, and immune-oncology mechanisms. With the rise of targeted therapies and checkpoint inhibitors, pharmaceutical companies and academic researchers increasingly rely on these models to evaluate drug efficacy and optimize dosing strategies before clinical trials. Their application in patient-derived xenograft (PDX) models is particularly valuable for studying tumor heterogeneity and treatment resistance. Additionally, regulatory agencies are recognizing the translational relevance of these models, further accelerating their integration into preclinical oncology pipelines and making this segment the epicenter of innovation in biomedical research.
By Type
By Application
By End-User
Geographical Analysis
*List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Humanized Mouse and Rat Model Market, encompassing current market size, growth trends, and forecasts till 2034.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Humanized Mouse and Rat Model Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2025 Humanized Mouse and Rat Model Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Humanized Mouse and Rat Model Market Size Outlook, $ Million, 2021 to 2030
3.2 Humanized Mouse and Rat Model Market Outlook by Type, $ Million, 2021 to 2030
3.3 Humanized Mouse and Rat Model Market Outlook by Product, $ Million, 2021 to 2030
3.4 Humanized Mouse and Rat Model Market Outlook by Application, $ Million, 2021 to 2030
3.5 Humanized Mouse and Rat Model Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Humanized Mouse and Rat Model Industry
4.2 Key Market Trends in Humanized Mouse and Rat Model Industry
4.3 Potential Opportunities in Humanized Mouse and Rat Model Industry
4.4 Key Challenges in Humanized Mouse and Rat Model Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Humanized Mouse and Rat Model Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Humanized Mouse and Rat Model Market Outlook by Segments
7.1 Humanized Mouse and Rat Model Market Outlook by Segments, $ Million, 2021- 2030
By Type
Humanized Mouse Model
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
Humanized Rat Model
By Application
Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Others
By End-User
Pharmaceutical & Biotechnology Companies
CROs and CDMOs
Research Institutes
Others
8 North America Humanized Mouse and Rat Model Market Analysis and Outlook To 2030
8.1 Introduction to North America Humanized Mouse and Rat Model Markets in 2024
8.2 North America Humanized Mouse and Rat Model Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Humanized Mouse and Rat Model Market size Outlook by Segments, 2021-2030
By Type
Humanized Mouse Model
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
Humanized Rat Model
By Application
Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Others
By End-User
Pharmaceutical & Biotechnology Companies
CROs and CDMOs
Research Institutes
Others
9 Europe Humanized Mouse and Rat Model Market Analysis and Outlook To 2030
9.1 Introduction to Europe Humanized Mouse and Rat Model Markets in 2024
9.2 Europe Humanized Mouse and Rat Model Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Humanized Mouse and Rat Model Market Size Outlook by Segments, 2021-2030
By Type
Humanized Mouse Model
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
Humanized Rat Model
By Application
Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Others
By End-User
Pharmaceutical & Biotechnology Companies
CROs and CDMOs
Research Institutes
Others
10 Asia Pacific Humanized Mouse and Rat Model Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Humanized Mouse and Rat Model Markets in 2024
10.2 Asia Pacific Humanized Mouse and Rat Model Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Humanized Mouse and Rat Model Market size Outlook by Segments, 2021-2030
By Type
Humanized Mouse Model
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
Humanized Rat Model
By Application
Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Others
By End-User
Pharmaceutical & Biotechnology Companies
CROs and CDMOs
Research Institutes
Others
11 South America Humanized Mouse and Rat Model Market Analysis and Outlook To 2030
11.1 Introduction to South America Humanized Mouse and Rat Model Markets in 2024
11.2 South America Humanized Mouse and Rat Model Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Humanized Mouse and Rat Model Market size Outlook by Segments, 2021-2030
By Type
Humanized Mouse Model
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
Humanized Rat Model
By Application
Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Others
By End-User
Pharmaceutical & Biotechnology Companies
CROs and CDMOs
Research Institutes
Others
12 Middle East and Africa Humanized Mouse and Rat Model Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Humanized Mouse and Rat Model Markets in 2024
12.2 Middle East and Africa Humanized Mouse and Rat Model Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Humanized Mouse and Rat Model Market size Outlook by Segments, 2021-2030
By Type
Humanized Mouse Model
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
Humanized Rat Model
By Application
Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Others
By End-User
Pharmaceutical & Biotechnology Companies
CROs and CDMOs
Research Institutes
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Aragen Life Sciences Pvt. Ltd
Biocytogen Inc
Champions Oncology Inc
Charles River Laboratories International Inc
Crown Bioscience Inc
Cyagen Biosciences Inc
GemPharmatech Co. Ltd
genOway S.A.
Harbour Antibodies BV
Hera BioLabs Inc
Ingenious Targeting Laboratory Inc
Inotiv Inc
Oncodesign SA
Ozgene Pty Ltd
Pharmatest Services Ltd
Taconic Biosciences Inc
The Jackson Laboratory
TRANS GENIC Inc
TransCure bioServices SAS
Vitalstar Biotechnology Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type
By Application
By End-User
Geographical Analysis
The Global Humanized Mouse and Rat Model Market Size is estimated at $289.5 Million in 2025 and is forecast to register an annual growth rate (CAGR) of 8.4% to reach $598.3 Million by 2034.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Aragen Life Sciences Pvt. Ltd, Biocytogen Inc, Champions Oncology Inc, Charles River Laboratories International Inc, Crown Bioscience Inc, Cyagen Biosciences Inc, GemPharmatech Co. Ltd, genOway S.A., Harbour Antibodies BV, Hera BioLabs Inc, Ingenious Targeting Laboratory Inc, Inotiv Inc, Oncodesign SA, Ozgene Pty Ltd, Pharmatest Services Ltd, Taconic Biosciences Inc, The Jackson Laboratory, TRANS GENIC Inc, TransCure bioServices SAS, Vitalstar Biotechnology Co. Ltd
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume